Including expert clinicals pioneering rapid neurological recovery with INR’s patented treatment
Perispinal etanercept is a method of targeting detrimental neuroinflammation using etanercept, a special anti-inflammatory drug, delivered utilizing a novel, non-invasive injection method.
Perispinal etanercept is NOT experimental. Perispinal etanercept has been used to treat more than 5,000 chronic stroke patients since 2010 at the Institute of Neurological Recovery.
No, it is not too late. Neuroinflammation can last for years, or even decades, after brain injury. Life-changing neurological improvements following perispinal etanercept treatment performed weeks, months, years, or even decades after stroke or brain injury are not uncommon.
Referrals are not required. The Institute of Neurological Recovery has received, and welcomes, referrals from neurologists, speech pathologists, physical therapists, occupational therapists, primary care physicians, online stroke groups, and, of course, patients and their family members.
Receive detailed information regarding the Institute’s unique, patented, anti-inflammatory treatment. We currently treat and accept new patients from around the world, even years or decades after stroke or traumatic brain injury.
Complete the form and a member of our team will be in touch shortly.
Edward Lewis Tobinick, M.D. is an American physician, inventor, and scientist. Dr. Tobinick is the inventor of the breakthrough perispinal etanercept (PSE) stroke treatment, as seen in the 60 Minutes Australia “Reverse Stroke” news feature and in hundreds of published videos (see the Institute of Neurological Recovery YouTube Channel). He has authored multiple, peer-reviewed, scientific publications in the field of neurology and granted more than 30 U.S. and international patents for his medical inventions. His work has been cited by more than 4900 scientific publications. His inventions include novel methods of drug delivery to selectively enhance the ability of large molecular weight drugs and biologics to reach the brain in therapeutic concentration. His medical discoveries have contributed to our fundamental understanding of brain and neuronal function in health and disease.
Notably, Dr. Tobinick invented and has refined methods of perispinal delivery of PSE for therapeutic use in neurology, novel inventions validated by a 2020 randomized, double-blind placebo-controlled clinical trial(1). The randomized trial documented “… rapid and wide-ranging benefits achievable by treating stroke patients with PSE,” findings supported by and originally reported in observational studies published by Dr. Tobinick and his colleagues beginning in 2011 (see below). In 2018 the Australian government designated funds specifically to run an additional randomized, controlled trial of PSE for stroke in Australia.
Dr. Tobinick graduated Phi Beta Kappa and Magna Cum Laude with honors in biology from Brandeis University in Waltham, Massachusetts, received his M.D. from the University of California San Diego School of Medicine in La Jolla, California, and completed residency training at UCLA. While in private practice in Beverly Hills and at 100 UCLA Medical Plaza, he also taught medical students, interns, residents and medical faculty as a clinical professor at UCLA for more than 20 years. He founded the Institute of Neurological Recovery in Los Angeles in 2001 and Boca Raton, Florida in 2011. He has been an invited expert reviewer for the journals Brain Research, Clinical Drug Investigation, CNS Drugs, Current Alzheimer Research, Drug Discovery Today, Experimental Neurology, Future Neurology, Journal of Neurochemistry, Journal of Neuroimmunology, Neuroscience, and Pharmaceutical Medicine and a member of the Editorial Board of the Journal of Neuroinflammation.
Dr. Tobinick has presented his scientific findings regarding PSE in neurology at multiple U.S. and international medical conferences, including the Alzheimer’s Drug Discovery Conference in New York in 2006; the Karolinska Institute in Stockholm in 2006; the Drug Repositioning Summit in Boston in 2008; the International Conference on Alzheimer’s Disease in Chicago in 2008; the Advances in Alzheimer’s Disease Management conference at the University of Arkansas Medical Sciences in Little Rock in 2008; and, in 2009, the 3rd International Restauracion Neurologica Conference in Havana, the World Pharmaceutical Congress in Philadelphia and the 5th Modern Drug Discovery Conference in San Diego. He has performed collaborative research with physicians and scientists at multiple academic centers, including Stanford University School of Medicine. Further randomized trials of PSE for stroke are in development, with the goal to achieve regulatory approval for PSE to help individuals recover from stroke, even years after the acute event.
Download a copy of Dr Tobinick’s 2016 Curriculum Vitae PDF Here.
Selected Scientific Publications Authored by Dr. Tobinick:
Additional information:
Originally from New York, Danielle relocated to South Florida in 2004 to pursue her studies at Palm Beach Atlantic University, where she earned a Bachelor of Science in Biology and Chemistry. She then went on to obtain her Master of Clinical Medical Science in Physician Assistant Studies from Barry University in 2013, graduating as the valedictorian of her class. That same year, she became board certified by the National Commission on Certification of Physician Assistants and was licensed to practice in Florida.
With a decade of experience in Internal Medicine, working closely with stroke and brain injury patients, Danielle joined the Institute in 2023 to further her passion for improving patient outcomes through innovative treatments. She has had intensive one-on-one training by Dr. Tobinick in the latest techniques for perispinal etanercept. She has worked alongside Dr. Tobinick during her entire time at the Institute. Danielle is currently accepting new patients at INR for stroke and brain injury treatment.
To schedule a phone consultation with Danielle, please complete our Request a Consultation form at https://www.nrimed.com/request-consultation/.
